Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human FOLH1B Stable Cell Line

    [CAT#: S01YF-1023-PY271]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Other Targets
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1
    Target Classification
    Other Targets Drug Discovery Assays and Products
    Gene ID
    Human:219595
    UniProt ID
    Human:#N/A

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    FOLH1B, a type II transmembrane protein, has been identified in various studies related to cancer biology. Its expression has been linked to certain types of cancers, making it a potential biomarker for disease diagnosis and progression. For instance, the presence of FOLH1B in semen has been associated with age prediction models, providing insights into reproductive health. Additionally, its mutation frequency in prostate cancer has been explored, suggesting its potential role in the development and progression of the disease.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human FOLH1B Stable Cell Line (S01YF-1023-PY271). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Alex Miller (Verified Customer)

    What is the significance of FOLH1B in prostate cancer? Feb 13 2020

    chat Patrick Liam (Creative Biolabs Scientific Support)

    FOLH1B has been identified as a high-frequency mutant gene in prostate cancer, suggesting its potential role in the disease's development and progression. Feb 13 2020

    chat Alex Smith (Verified Customer)

    How does FOLH1B relate to the tumor-immune microenvironment in endometrial cancer? Mar 28 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    FOLH1B is associated with the immune-tumor microenvironment and prognosis in endometrial cancer, indicating its significance in immune-related mechanisms and as a prognostic predictor. Mar 28 2021

    Published Data

    Fig.1 Sox7 expression negatively correlates with FOLH1 or FOLH1B expression in prostate cancer studies.

    In prostate cancer studies, a negative correlation between FOLH1 or FOLH1B expression and Sox7 expression was observed, with RNA expression data retrieved from cBioPortal. The Pearson Correlation Coefficient (r) and P-value were determined via PROC CORR in SAS for Broad/Cornell and MSKCC studies, while Spearman Rank Correlation Coefficient was utilized for the TCGA study due to the non-normal data distribution. Additionally, simple linear regression (SLR) analysis was conducted to assess the direction and strength of the linear relationship between Sox7 and FOLH1 as well as Sox7 and FOLH1B, with estimates of the true slope (solid line), P-value, 95% confidence intervals (shaded area), and 95% prediction intervals (dotted line) being obtained through PROC REG in SAS.

    Ref: Peng, Wei, et al. "Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer." The Prostate 79.4 (2019): 370-378.

    Pubmed: 30488457

    DOI: 10.1002/pros.23743

    Research Highlights

    Pisarek, Aleksandra. et al. "Epigenetic age prediction in semen - marker selection and model development." Aging, 2021.
    Recent years have seen an increase in the utilization of DNA methylation analysis in both biomedical research and forensic practice. The identification of differentially methylated sites (DMSs) that exhibit varying levels of methylation throughout an individual's lifetime has led to significant advancements in molecular age estimation. Despite the common use of semen samples in forensic DNA analysis, previous studies on epigenetic age prediction have primarily focused on somatic cell types. A new study utilized Infinium MethylationEPIC BeadChip arrays to analyze DNA samples derived from semen, uncovering multiple novel DMSs that show moderate correlation with age. By validating the top ten most age-correlated DMSs, as well as three previously known markers, using targeted bisulfite massively parallel sequencing with an independent set of semen samples, the study confirmed the age-correlated nature of nine newly identified and three previously known DMSs. Prediction modelling identified a reliable model for semen, built on six CpGs from the newly identified genes.
    Pisarek, Aleksandra. et al. "Epigenetic age prediction in semen - marker selection and model development." Aging, 2021.
    Pubmed: 34375949   DOI: 10.18632/aging.203399

    Peng, Wei. et al. "Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer." The Prostate, 2019.
    In this study, it was found that the cis-element, PSMA enhancer (PSME), is responsible for controlling the expression of PSMA in the prostate epithelium. PSME contains several binding sites for Sox proteins, with the identification of Sox7 protein as a negative regulator of PSMA expression due to its interaction with PSME. This discovery sheds light on the role of PSME and Sox7 protein in regulating PSMA expression in the prostate epithelium.
    Peng, Wei. et al. "Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer." The Prostate, 2019.
    Pubmed: 30488457   DOI: 10.1002/pros.23743

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare